Predictive value of a novel sub-item mortality risk score derived from the Norfolk Quality of Life in Diabetic Neuropathy questionnaire in Romanian participants with diabetes mellitus.

Autor: Bondor CI; Department of Medical Informatics and Biostatistics, Iuliu Haţieganu University of Medicine and Pharmacy, 6 Pasteur street, 400349 Cluj-Napoca, Romania. Electronic address: cosmina_ioana@yahoo.com., Cosma DT; Cluj-Napoca County Emergency Hospital, Centre of Diabetes, Nutrition and Metabolic Diseases, 2 Clinicilor street, 400006 Cluj-Napoca, Romania., Florea B; Podiatry Clinic, 10 Iuliu Moldovan street, 400348 Cluj-Napoca, Romania., Sima DI; Department of Diabetes, Nutrition and Metabolic Diseases, Iuliu Haţieganu University of Medicine and Pharmacy, 4-6 Clinicilor street, 400006 Cluj-Napoca, Romania., Tăuţ A; Cluj-Napoca County Emergency Hospital, Centre of Diabetes, Nutrition and Metabolic Diseases, 2 Clinicilor street, 400006 Cluj-Napoca, Romania., Vereşiu IA; Department of Diabetes, Nutrition and Metabolic Diseases, Iuliu Haţieganu University of Medicine and Pharmacy, 4-6 Clinicilor street, 400006 Cluj-Napoca, Romania., Vinik EJ; Strelitz Diabetes Centre, Eastern Virginia Medical School, 855 West Brambleton Avenue, Norfolk, VA 23510, USA., Vinik A; Research & Neuroendocrine Unit, Eastern Virginia Medical School, 855 West Brambleton Avenue, Norfolk, VA 23510, USA., Vonica C; Department of Diabetes, Nutrition and Metabolic Diseases, Iuliu Haţieganu University of Medicine and Pharmacy, 4-6 Clinicilor street, 400006 Cluj-Napoca, Romania., Gâvan NA; Wörwag Pharma Romania SRL, 21 Gării street, 400267 Cluj-Napoca, Romania.
Jazyk: angličtina
Zdroj: Primary care diabetes [Prim Care Diabetes] 2022 Oct; Vol. 16 (5), pp. 684-691. Date of Electronic Publication: 2022 Jul 30.
DOI: 10.1016/j.pcd.2022.07.005
Abstrakt: Aims: To evaluate whether the Norfolk Quality of Life in Diabetic Neuropathy (QOL-DN) questionnaire and the novel Norfolk Mortality Risk Score (NMRS), comprising Norfolk QOL-DN items, can identify 4-year mortality risk in individuals with diabetes.
Methods: Of 21,756 adults completing Norfolk QOL-DN in 2012, two groups of surviving and deceased patients were identified in 2016: Group 1, from a county capital and Group 2, from six small cities. NMRS was calculated in Group 1 using the 2012 scores of Norfolk QOL-DN items that discriminate between deceased and surviving participants (p < 0.05) and was subsequently applied to Group 2.
Results: 763 participants were included (Group 1: 481 [450 surviving, 31 deceased]; Group 2: 282 [218 surviving, 64 deceased]). Total Norfolk QOL-DN score was significantly higher (worse) in deceased participants than in survivors in both groups (p ≤ 0.008). Optimal cut-off for the 25-item NMRS was 11.5 in Group 1. Individuals in Groups 1 and 2 with NMRS≥ 11.5 in 2012 had a 4-year mortality risk ratio of 4.24 (95 % confidence interval [CI]: 1.65-10.84) and 2.33 (95 % CI: 1.33-4.07), respectively, corresponding to 8 and 16 additional deaths/100 persons/4 years (p = 0.001).
Conclusion: Norfolk QOL-DN and NMRS can identify individuals with diabetes at risk of 4-year mortality.
Competing Interests: Declaration of interests A. Vinik has a patent copyright of the Norfolk QOL-DN. Eastern Virginia Medical School (EVMS). Royalties were paid to E.J. Vinik and A. Vinik by EVMS when the Norfolk QOL-DN was licensed previously by Wörwag from EVMS in 2012. No fees have been paid to them by Wörwag subsequently and they declare no financial relationship. C.I. Bondor reports personal fees and non-financial support from Wörwag Pharma GmbH & Co. KG, Romanian Rep. Office, during the conduct of the study. D.-T. Cosma and D. Sima report non-financial support from Wörwag Pharma GmbH&Co.KG, during the conduct of the study, and outside the submitted work.I.A. Vereşiu reports personal fees from Sanofi Romania, AstraZeneca Romania and Novo Nordisk Romania, personal fees and non-financial support from MSD Romania and Wörwag Pharma GmbH&Co.KG, outside the submitted work. N.A. Gâvan is an employee of Wörwag Pharma GmbH & Co. KG, Romanian Rep. Office. B. Florea, A. Tăuţ and C. Vonica have nothing to disclose.
(Copyright © 2022. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: